BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare era corporate leveraging biomarkers and proprietary augmented intelligence (AI) algorithms via its Nociscan platform to assist physicians establish the positioning of persistent low again ache and reinforce progressed remedy luck charges, these days introduced that its Board of Administrators has licensed a percentage repurchase program of as much as $2.5 million of the Corporate’s exceptional commonplace inventory.
Aclarion expects to execute the repurchase program over the following three hundred and sixty five days. The timing, quantity, and nature of repurchases can be made up our minds by way of the Corporate in keeping with elements together with marketplace prerequisites, percentage worth, liquidity, and operational and strategic priorities. This system does no longer obligate the Corporate to obtain any explicit collection of stocks, and is also suspended, changed, or discontinued at any time.
The Corporate intends to fund the repurchase program the usage of present money and money equivalents.
“This authorization underscores our commitment to disciplined capital allocation and our belief that Aclarion’s current valuation does not fully reflect the strength of our platform and long-term growth opportunity,” mentioned Brent Ness, Leader Government Officer of Aclarion. “We believe our shares represent a compelling value at current levels, and we view this program as a flexible and opportunistic tool to enhance shareholder value while continuing to invest in the clinical adoption and expansion of Nociscan.”
As of March 31, 2026, the Corporate had money and money equivalents of roughly $19.0 million, which control believes supplies enough runway to reinforce operations via key upcoming milestones, together with the preliminary milestone of the CLARITY randomized trial.
Greg Gould, Leader Monetary Officer of Aclarion, added, “We are focused on balancing investment in growth with prudent capital management. Given our current capital position and expected operating needs, we believe a share repurchase program is an efficient and disciplined way to deploy capital while maintaining the financial flexibility necessary to execute on our strategic priorities.”
Repurchases beneath this system is also made every now and then, in quantities, at costs, and at such instances because the Corporate deems suitable, topic to marketplace prerequisites and different issues, in compliance with appropriate federal and state securities rules, together with Regulations 10b5-1 and 10b-18 beneath the Securities Change Act of 1934, as amended. Repurchases is also completed via quite a few strategies, together with open marketplace purchases, privately negotiated transactions, block trades, speeded up percentage repurchase transactions, or pursuant to Rule 10b5-1 buying and selling plans, which might allow the Corporate to repurchase stocks all through sessions when it might differently be limited from doing so.
To discover a Nociscan middle, view our website online map right here.
About Aclarion, Inc.
Aclarion is a healthcare era corporate that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing tactics, biomarkers, and augmented intelligence algorithms to optimize scientific remedies. The Corporate is first addressing the persistent low again ache marketplace with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar backbone. Thru a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI device for every lumbar disc being evaluated. Within the cloud, proprietary sign processing tactics extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to signify if a disc is also a supply of ache. When used with different diagnostic gear, Nociscan supplies crucial insights into the positioning of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For more info, please discuss with www.aclarion.com.
Ahead Having a look Statements
This press free up comprises forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Segment 27A of the Securities Act of 1933 and Segment 21E of the Securities Change Act of 1934 in regards to the Corporate’s present expectancies about long term effects, efficiency, potentialities and alternatives. Statements that don’t seem to be historic information, akin to “anticipates,” “believes” and “expects” or an identical expressions, are forward-looking statements. Those forward-looking statements are in keeping with the present plans and expectancies of control and are topic to quite a lot of uncertainties and dangers that might considerably impact the Corporate’s present plans and expectancies, in addition to long term result of operations and monetary situation. Ahead-looking statements on this free up come with, amongst others, statements in regards to the expectation to execute the repurchase program over the following three hundred and sixty five days, that the Corporate intends to fund the repurchase program the usage of present money and money equivalents, control’s trust that the $19.0 million at March 31, 2026 supplies enough runway to reinforce operations via key upcoming milestones, together with the preliminary milestone of the CLARITY randomized trial, and the prospective advantages of our Nociscan era. Those and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Change Fee. Readers are inspired to study the phase titled “Risk Factors” within the Corporate’s Annual File on Shape 10-Ok for the yr ended December 31, 2025, in addition to different disclosures contained within the Prospectus and next filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Corporate undertakes no legal responsibility to publicly replace or revise any forward-looking statements, whether or not because of new data, long term occasions or differently.
Investor Contacts:
Media Contacts:
